Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H22ClN3O |
Molecular Weight | 355.8619 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)Cc1cc(ccc1O)Nc2ccnc3cc(ccc23)Cl
InChI
InChIKey=OVCDSSHSILBFBN-UHFFFAOYSA-N
InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)
Molecular Formula | C20H22ClN3O |
Molecular Weight | 355.8619 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00613 | https://www.drugs.com/international/amodiaquine.html | https://www.ncbi.nlm.nih.gov/pubmed/9825729 | https://www.ncbi.nlm.nih.gov/pubmed/22949374 | https://www.ncbi.nlm.nih.gov/pubmed/18855526
Curator's Comment:: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00613 | https://www.drugs.com/international/amodiaquine.html | https://www.ncbi.nlm.nih.gov/pubmed/9825729 | https://www.ncbi.nlm.nih.gov/pubmed/22949374 | https://www.ncbi.nlm.nih.gov/pubmed/18855526
Amodiaquine is a medication used to treat malaria, including Plasmodium falciparum malaria when uncomplicated. The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. The drug binds the free heme preventing the parasite from converting it to a form less toxic. This drug-heme complex is toxic and disrupts membrane function. The side effects of amodiaquine are generally minor to moderate and are similar to those of chloroquine. Rarely liver problems or low blood cell levels may occur. When taken in excess headaches, trouble seeing, seizures, and cardiac arrest may occur. After oral administration amodiaquine hydrochloride is rapidly absorbed,and undergoes rapid and extensive metabolism to desethylamodiaquine which concentrates in red blood cells. It is likely that desethylamodiaquine, not amodiaquine, is responsible for most of the observed antimalarial activity, and that the toxic effects of amodiaquine after oral administration may in part be due to desethylamodiaquine.
CNS Activity
Curator's Comment:: Although in use for more than 40 year, there exists little information regarding the disposition of amodiaquine in man. Chloroquine, a 4-aminoquinoline derivative which resembles amodiaquine structurally, is widely distributed into the body tissues, especially in liver, spleen, kidney, lungs, brain, and spinal cord.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Heme degradation by glutathione Sources: https://www.ncbi.nlm.nih.gov/pubmed/9825729 |
|||
Target ID: Heme polymerization |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Coarsucam Approved UseTherapeutic Indication. ARTESUNATE AMODIAQUINE WINTHROP is indicated for the treatment of uncomplicated cases of malaria due to Plasmodium falciparum strains which are susceptible to amodiaquine as well as to artesunate. |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8983859/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
AMODIAQUINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
322 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8983859/ |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMODIAQUINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
415 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8983859/ |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMODIAQUINE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
77 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8983859/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
AMODIAQUINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8983859/ |
10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
AMODIAQUINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8983859/ |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMODIAQUINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8983859/ |
10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMODIAQUINE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20368402/ |
270 mg 1 times / day steady-state, oral dose: 270 mg route of administration: Oral experiment type: STEADY-STATE co-administered: ARTESUNATE |
AMODIAQUINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
73.4 mg 1 times / day multiple, oral (mean) Studied dose Dose: 73.4 mg, 1 times / day Route: oral Route: multiple Dose: 73.4 mg, 1 times / day Sources: |
unhealthy, 17 to 76 years n = 7 Health Status: unhealthy Condition: malaria Age Group: 17 to 76 years Sex: M+F Population Size: 7 Sources: |
Other AEs: Agranulocytosis... |
10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
healthy, 18 to 45 years n = 15 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 15 Sources: |
Disc. AE: Hypersensitivity reaction... AEs leading to discontinuation/dose reduction: Hypersensitivity reaction (6.7%) Sources: |
10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
healthy, 18 to 45 years n = 7 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 7 Sources: |
Other AEs: Leucopenia, Neutropenia... Other AEs: Leucopenia (grade 1, 14%) Sources: Neutropenia (grade 1, 14%) |
10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Co-administed with:: artesunate(4 mg/kg; single dose) Sources: |
healthy, 18 to 45 years n = 8 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Neutropenia... |
10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
healthy, 18 to 45 years n = 8 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 8 Sources: |
Other AEs: Transaminitis... |
45 mg/kg multiple, oral (mean) Studied dose Dose: 45 mg/kg Route: oral Route: multiple Dose: 45 mg/kg Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: onchocerciasis Age Group: adult Sex: M Population Size: 20 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (35%) Sources: Vomiting (35%) Lassitude (grade 2, 60%) Diarrhoea (15%) Constipation (10%) Granulocytopenia (15%) |
600 mg 1 times / day multiple, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, median age 20 years n = 220 Health Status: unhealthy Condition: malaria Age Group: median age 20 years Sex: F Population Size: 220 Sources: |
Other AEs: Weakness generalised, Dizziness... Other AEs: Weakness generalised (84%) Sources: Dizziness (58%) Vomiting (46%) Itching (32%) Nausea (26%) |
71.6 mg 1 times / day multiple, oral (mean) Studied dose Dose: 71.6 mg, 1 times / day Route: oral Route: multiple Dose: 71.6 mg, 1 times / day Sources: |
unhealthy, median age 35 years n = 2 Health Status: unhealthy Condition: malaria Age Group: median age 35 years Sex: M+F Population Size: 2 Sources: |
Other AEs: Hepatotoxicity... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agranulocytosis | 73.4 mg 1 times / day multiple, oral (mean) Studied dose Dose: 73.4 mg, 1 times / day Route: oral Route: multiple Dose: 73.4 mg, 1 times / day Sources: |
unhealthy, 17 to 76 years n = 7 Health Status: unhealthy Condition: malaria Age Group: 17 to 76 years Sex: M+F Population Size: 7 Sources: |
|
Hypersensitivity reaction | 6.7% Disc. AE |
10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
healthy, 18 to 45 years n = 15 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 15 Sources: |
Leucopenia | grade 1, 14% | 10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
healthy, 18 to 45 years n = 7 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 7 Sources: |
Neutropenia | grade 1, 14% | 10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
healthy, 18 to 45 years n = 7 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 7 Sources: |
Neutropenia | grade 2, 12% | 10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Co-administed with:: artesunate(4 mg/kg; single dose) Sources: |
healthy, 18 to 45 years n = 8 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 8 Sources: |
Transaminitis | grade 3, 12% | 10 mg/kg 1 times / day single, oral Studied dose Dose: 10 mg/kg, 1 times / day Route: oral Route: single Dose: 10 mg/kg, 1 times / day Sources: |
healthy, 18 to 45 years n = 8 Health Status: healthy Age Group: 18 to 45 years Sex: M+F Population Size: 8 Sources: |
Constipation | 10% | 45 mg/kg multiple, oral (mean) Studied dose Dose: 45 mg/kg Route: oral Route: multiple Dose: 45 mg/kg Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: onchocerciasis Age Group: adult Sex: M Population Size: 20 Sources: |
Diarrhoea | 15% | 45 mg/kg multiple, oral (mean) Studied dose Dose: 45 mg/kg Route: oral Route: multiple Dose: 45 mg/kg Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: onchocerciasis Age Group: adult Sex: M Population Size: 20 Sources: |
Granulocytopenia | 15% | 45 mg/kg multiple, oral (mean) Studied dose Dose: 45 mg/kg Route: oral Route: multiple Dose: 45 mg/kg Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: onchocerciasis Age Group: adult Sex: M Population Size: 20 Sources: |
Nausea | 35% | 45 mg/kg multiple, oral (mean) Studied dose Dose: 45 mg/kg Route: oral Route: multiple Dose: 45 mg/kg Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: onchocerciasis Age Group: adult Sex: M Population Size: 20 Sources: |
Vomiting | 35% | 45 mg/kg multiple, oral (mean) Studied dose Dose: 45 mg/kg Route: oral Route: multiple Dose: 45 mg/kg Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: onchocerciasis Age Group: adult Sex: M Population Size: 20 Sources: |
Lassitude | grade 2, 60% | 45 mg/kg multiple, oral (mean) Studied dose Dose: 45 mg/kg Route: oral Route: multiple Dose: 45 mg/kg Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: onchocerciasis Age Group: adult Sex: M Population Size: 20 Sources: |
Nausea | 26% | 600 mg 1 times / day multiple, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, median age 20 years n = 220 Health Status: unhealthy Condition: malaria Age Group: median age 20 years Sex: F Population Size: 220 Sources: |
Itching | 32% | 600 mg 1 times / day multiple, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, median age 20 years n = 220 Health Status: unhealthy Condition: malaria Age Group: median age 20 years Sex: F Population Size: 220 Sources: |
Vomiting | 46% | 600 mg 1 times / day multiple, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, median age 20 years n = 220 Health Status: unhealthy Condition: malaria Age Group: median age 20 years Sex: F Population Size: 220 Sources: |
Dizziness | 58% | 600 mg 1 times / day multiple, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, median age 20 years n = 220 Health Status: unhealthy Condition: malaria Age Group: median age 20 years Sex: F Population Size: 220 Sources: |
Weakness generalised | 84% | 600 mg 1 times / day multiple, oral Studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, median age 20 years n = 220 Health Status: unhealthy Condition: malaria Age Group: median age 20 years Sex: F Population Size: 220 Sources: |
Hepatotoxicity | 71.6 mg 1 times / day multiple, oral (mean) Studied dose Dose: 71.6 mg, 1 times / day Route: oral Route: multiple Dose: 71.6 mg, 1 times / day Sources: |
unhealthy, median age 35 years n = 2 Health Status: unhealthy Condition: malaria Age Group: median age 35 years Sex: M+F Population Size: 2 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | yes (co-administration study) Comment: When administered with efavirenz, 125%, 78%, 80%, and 42.15% increase in the Tmax, Cmax AUCT and T1/2 of amodiaquine respectively |
|||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
unlikely | unlikely Comment: Since artesunate is mainly metabolized by CYP2A6, drug–drug interaction between artesunate and AQ is unlikely to occur |
|||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[Developments in anti-malaria agents: chemical data, structure-activity relationships]. | 2001 Apr |
|
Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. | 2001 Aug |
|
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. | 2001 Aug 4 |
|
Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. | 2001 Jan |
|
Evaluation under field conditions of the colourimetric DELI-microtest for the assessment of Plasmodium falciparum drug resistance. | 2001 Jan-Feb |
|
Improved assay method for the determination of pyronaridine in plasma and whole blood by high-performance liquid chromatography for application to clinical pharmacokinetic studies. | 2001 Mar 5 |
|
[National Network study to perpetuate the surveillance of Plasmodium falciparum sensitivity to antimalarials in Madagascar]. | 2002 |
|
[Center of multidrug-resistant malaria in a forest zone of Cameroon revisited after 14 years]. | 2002 |
|
Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. | 2002 |
|
Resistance of Plamodium falciparum to antimalarial drugs in Zaragoza (Antioquia, Colombia), 1998. | 2002 Apr |
|
Molecular epidemiology of malaria in cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children. | 2002 Feb |
|
The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. | 2002 Jul |
|
Molecular epidemiology of malaria in Cameroon. X. Evaluation of PFMDR1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. | 2002 Jun |
|
The effects of chloroquine, amodiaquine and chloroquine plus chlorpheniramine on the disposition kinetics of the hepatomegaly associated with acute, uncomplicated, Plasmodium falciparum malaria in children. | 2002 Sep |
|
Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of Plasmodium. | 2003 |
|
Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. | 2003 Apr 1 |
|
Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. | 2003 Aug |
|
Epidemiological models for the spread of anti-malarial resistance. | 2003 Feb 19 |
|
Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. | 2003 Jun |
|
[Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002]. | 2003 Mar |
|
Conductometric and indirect AAS determination of antimalarials. | 2003 Mar 26 |
|
Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, south Sudan. | 2003 Mar-Apr |
|
Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. | 2003 Nov 6 |
|
Amodiaquine treatment of uncomplicated malaria in children, in an area of chloroquine-resistant Plasmodium falciparum in north-central Nigeria. | 2003 Oct |
|
Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. | 2003 Oct 15 |
|
Polymorphism in the Plasmodium falciparum chloroquine-resistance transporter protein links verapamil enhancement of chloroquine sensitivity with the clinical efficacy of amodiaquine. | 2003 Sep 19 |
|
[Pyrido [3,2-b]indol-4-yl-amines--synthesis and investigation of activity against malaria]. | 2004 Apr |
|
A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. | 2004 Apr |
|
Human liver aldehyde oxidase: inhibition by 239 drugs. | 2004 Jan |
|
Efficacy of pyrimethamine-sulfadoxine in young children with uncomplicated falciparum malaria in rural Burkina Faso. | 2004 May 11 |
Patents
Sample Use Guides
For the treatment of acute malarial attacks in non-immune subjects: 600 mg of the base, followed by 200 mg after 6 hours, then 400 mg daily on each of the subsequent two days. Doses may be taken with meals to lessen gastric upset.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9825729
The FCR3 strain of Plasmodium falciparum was synchronized and cultivated to the trophozoite stage. Synchronized cultures were seeded at the ring stage and allowed to grow for another 20 hr until most parasites reached the trophozoite stage; parasitemia and cell number were determined, and cultures were cultured 6 drug for 1,2,3 and 4 h. One milliliter of culture was washed twice in wash medium (culture medium without plasma, 37°) to remove the drug, and cells were seeded in 24-well culture plates in full culture medium supplemented with 5 mCi/mL of [3H]hypoxanthine. After 4 hr of further cultivation, triplicate samples were transferred into 96-well plates, and parasiteassociated radioactivity was determined using the Filtermate/Matrix 96 Direct Beta counter. Inhibition of parasite growth was calculated compared to untreated controls.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:56:40 UTC 2021
by
admin
on
Fri Jun 25 20:56:40 UTC 2021
|
Record UNII |
220236ED28
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.3.1
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
||
|
LIVERTOX |
47
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
||
|
NCI_THESAURUS |
C271
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
||
|
WHO-ATC |
P01BA06
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.3.1 (ART/AMO)
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
||
|
WHO-ATC |
P01BF03
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D000655
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
201-669-3
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
SUB05470MIG
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
AMODIAQUINE
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | Description: A yellow, crystalline powder; odourless. Solubility: Practically insoluble in water. Category: Antimalarial drug. Storage: Amodiaquine should be kept in a tightly closed container. Definition: Amodiaquine contains not less than 97.0% and not more than 103.0% of C20H22ClN3O, calculated with reference to the anhydrous substance. | ||
|
2165
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
DB00613
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
CHEMBL682
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
220236ED28
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
C65231
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
86-42-0
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
186
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
720
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | RxNorm | ||
|
1116
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
7457
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
M1839
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | Merck Index | ||
|
AMODIAQUINE
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY | |||
|
86-42-0
Created by
admin on Fri Jun 25 20:56:40 UTC 2021 , Edited by admin on Fri Jun 25 20:56:40 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |